Investigational vaccine effective against Meningococcal Serogroup B

A multicomponent serogroup B Neisseria meningitides vaccine (4CMenB) has been found to be immunogenic against three reference strains when administered with routine vaccines at either two, four, and six or two, three, and four months, and in addition, it produces minimal interference with routine infant vaccinations. The study included 1,885 healthy infants. After immunization with 4CMenB and routine vaccines together at either two, four, and six or two, three, and four months, 99% or more of participants had human complement serum bactericidal activity (hSBA) titers of 1:5 or greater for strains 44/76-SL and 5/99. For the vaccine antigen NZ98/254, the proportion of infants with hSBA titers of 1:5 or greater was 79% (95% confidence interval [CI], 75.2% – 82.4%) for vaccination at two, four, and six months with routine vaccine; 86.1% (95% CI, 82.9% – 89.0%) for vaccination at two, four, and six months without routine vaccines; and 81.7% (95% CI,...